Rani Therapeutics Holdings (RANI) Profit After Tax (2020 - 2026)

Rani Therapeutics Holdings' Profit After Tax history runs 7 years deep, the most recent figure standing at -$7.0 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 44.79% year-over-year to -$7.0 million; the TTM figure through Mar 2026 stood at -$45.3 million (up 6.9% YoY), while the FY2025 annual figure was -$40.9 million, up 27.63% from the prior year.
• Profit After Tax for Q1 2026 stood at -$7.0 million, up from -$21.6 million in the prior quarter.
• The five-year high for Profit After Tax was $19.9 million in Q4 2023, with the low at -$41.5 million in Q4 2022.
• The 5-year median for Profit After Tax is -$13.8 million (2022), against an average of -$13.0 million.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax slumped 212.23% in 2022, then jumped 147.8% in 2023.
• Rani Therapeutics Holdings' Profit After Tax stood at -$41.5 million in 2022, then surged by 147.8% to $19.9 million in 2023, then tumbled by 179.17% to -$15.7 million in 2024, then tumbled by 37.27% to -$21.6 million in 2025, then soared by 67.41% to -$7.0 million in 2026.
• Business Quant data shows RANI's Profit After Tax at -$7.0 million in Q1 2026, -$21.6 million in Q4 2025, and -$5.4 million in Q3 2025.